N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 / Phase 3 ClinicalTrials.gov

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Sponsor: Corxel Pharmaceuticals • ClinicalTrials.gov ID: NCT06990867

Registry updated: 2026-09-21
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS. 2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS. During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.

Interventions

  • JX10 (Drug)
    JX10 is a thrombolytic agent.
  • Placebo (Drug)
    Placebo is being used as the comparator.

Eligibility criteria

Inclusion Criteria: 1. Age ≥ 18 and ≤ 90 years old. 2. Acute ischemic stroke with compatible clinical presentation and symptomatic high grade or complete occlusion of the intracranial internal carotid, M1, M2 or distal branches of the middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA). 3. Radiographic evidence of salvageable tissue. 4. Pre-treatment score of NIHSS ≥ 5. Exclusion Criteria: 1. Radiographic findings pre-randomization of any of the following: 1. Large core infarction, or 2. Occlusion in more than 1 vascular territory, or 3. Significant mass effect or clinically significant cerebral edema, or 4. Evidence of acute intracranial or extracranial hemorrhage, intracranial tumor (except small meningioma), neoplasm, or arteriovenous malformation), or 5. Clinical history, past imaging, or clinical judgement suggests that the intracranial occlusion is chronic. 2. Medical history or active clinically significant bleeding, lesions, or conditions (at the investigator's judgement) considered to be of significant risk for major bleeding. 3. Severe, uncontrolled hypertension (systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) that cannot be controlled with antihypertensive therapy. 4. Known bleeding diathesis (hereditary or acquired) or any significant coagulopathy. Specifically, platelet count \< 100,000/μL, international normalized ratio \> 1.7, aPTT \> 40 seconds, or prothrombin time \> 15 seconds. 5. Major trauma, surgery, or invasive procedures. 6. Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations of this study. 7. Pre-treatment blood glucose \> 400 mg/dL (22.20 mmol/L) or Pre-treatment blood glucose \< 50 mg/dL (2.78 mmol/L) unless it is corrected prior to study treatment administration. Participants with subsequently normalized blood glucose levels may be considered for inclusion, per Investigator judgement.

Conditions

Acute Ischemic Stroke

Locations

  • Corxel Investigational Site — Long Beach, California, United States
  • Corxel Investigational Site — Los Angeles, California, United States
  • Corxel Investigational Site — Sacramento, California, United States
  • Corxel Investigational Site — Colorado Springs, Colorado, United States
  • Corxel Investigational Site — Washington D.C., District of Columbia, United States
  • Corxel Investigational Site — Delray Beach, Florida, United States
  • Corxel Investigational Site — Chicago, Illinois, United States
  • Corxel Investigational Site — Wichita, Kansas, United States
  • Corxel Investigational Site — Baltimore, Maryland, United States
  • Corxel Investigational Site — Kalamazoo, Michigan, United States
  • Corxel Investigational Site — Traverse City, Michigan, United States
  • Corxel Investigational Site — St Louis, Missouri, United States
  • Corxel Investigational Site — Great Neck, New York, United States
  • Corxel Investigational Site — New York, New York, United States
  • Corxel Investigational Site — Columbus, Ohio, United States
  • Corxel Investigational Site — Toledo, Ohio, United States
  • Corxel Investigational Site — Tulsa, Oklahoma, United States
  • Corxel Investigational Site — Chattanooga, Tennessee, United States
  • Corxel Investigational Site — Dallas, Texas, United States
  • Corxel Investigational Site — Houston, Texas, United States
  • Corxel Investigational Site — Ghent, Belgium
  • Corxel Investigational Site — Hasselt, Belgium
  • Corxel Investigational Site — Blagoevgrad, Bulgaria
  • Corxel Investigational Site — Burgas, Bulgaria
  • Corxel Investigational Site — Pleven, Bulgaria
  • Corxel Investigational Site — Plovdiv, Bulgaria
  • Corxel Investigational Site — Sofia, Bulgaria
  • Corxel Investigational Site — Edmonton, Canada
  • Corxel Investigational Site — Kingston, Canada
  • Corxel Investigational Site — Winnipeg, Canada
  • Corxel Investigational Site — Baotou, China
  • Corxel Investigational Site — Beijing, China
  • Corxel Investigational Site — Beijing, China
  • Corxel Investigational Site — Changchun, China
  • Corxel Investigational Site — Guangzhou, China
  • Corxel Investigational Site, — Harbin, China
  • Corxel Investigational Site — Harbin, China
  • Corxel Investigational Site — Kaili, China
  • Corxel Investigational Site — Linfen, China
  • Corxel Investigational Site — Nanyang, China
  • Corxel Investigational Site — Shanghai, China
  • Corxel Investigational Site — Shenyang, China
  • Corxel Investigational Site — Suzhou, China
  • Corxel Investigational Site — Weifang, China
  • Corxel Investigational Site — Xuzhou, China
  • Corxel Investigational Site — Zhangjiakou, China
  • Corxel Investigational site — Lille, France
  • Corxel Investigational Site — Nancy, France
  • Corxel Investigational site — Paris, France
  • Corxel Investigational Site — Rouen, France
  • Corxel Investigational Site — Toulouse, France
  • Corxel Investigational Site — Tours, France
  • Corxel Investigational Site — Altenburg, Germany
  • Corxel Investigational Site — Frankfurt, Germany
  • Corxel Investigational Site — Leipzig, Germany
  • Corxel Investigational Site — Lübeck, Germany
  • Corxel Investigational Site — Trier, Germany
  • Corxel Investigational Site — Athens, Greece
  • Corxel Investigational Site — Chaïdári, Greece
  • Corxel Investigational Site — Pátrai, Greece
  • Corxel Investigational Site — Thessaloniki, Greece
  • Corxel Investigational Site — Budapest, Hungary
  • Corxel Investigational Site — Pavia, Italy
  • Corxel Investigational Site — Roma, Italy
  • Corxel Investigational Site — Fukuoka, Japan
  • Corxel Investigational Site — Hyōgo, Japan
  • Corxel Investigational site — Ibaraki, Japan
  • Corxel Investigational Site — Kamakura, Japan
  • Corxel Investigational Site — Meguro City, Japan
  • Corxel Investigational Site — Mitaka, Japan
  • Corxel Investigational Site — Miyagi, Japan
  • Corxel Investigational site — Toyota, Japan
  • Corxel Investigational Site — Yamagata, Japan
  • Corxel Investigational Site — Yamaguchi, Japan
  • Corxel Investigational Site — Daugavpils, Latvia
  • Corxel Investigational Site — Riga, Latvia
  • Corxel Investigational Site — Kaunas, Lithuania
  • Corxel Investigational Site — Vilnius, Lithuania
  • Corxel Investigational Site — Kuching, Malaysia
  • Corxel Investigational Site — Almada, Portugal
  • Corxel Investigational Site — Braga, Portugal
  • Corxel Investigational Site — Faro, Portugal
  • Corxel Investigational Site — Loures, Portugal
  • Corxel Investigational Site — Matosinhos Municipality, Portugal
  • Corxel Investigational Site — Belgrade, Serbia
  • Corxel Investigational Site — Kragujevac, Serbia
  • Corxel Investigational Site — Niš, Serbia
  • Corxel Investigational Site — Novi Sad, Serbia
  • Corxel Investigational Site — Seoul, South Korea
  • Corxel Investigational Site — A Coruña, Spain
  • Corxel Investigational Site — Albacete, Spain
  • Corxel Investigational Site — Barcelona, Spain
  • Corxel Investigational Site — Girona, Spain
  • Corxel Investigational Site — Madrid, Spain
  • Corxel Investigational Site — Madrid, Spain
  • Corxel Investigational Site — Málaga, Spain
  • Corxel Investigational Site — Seville, Spain
  • Corxel Investigational Site — Valencia, Spain
  • Corxel Investigational Site — Bangkok, Thailand
  • Corxel Investigational Site — Khon Kaen, Thailand
  • Corxel Investigational Site — London, United Kingdom
  • Corxel Investigational Site — Stoke-on-Trent, United Kingdom
  • Corxel Investigational Site — Hanoi, Vietnam
  • Corxel Investigational Site — Ho Chi Minh City, Vietnam
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record